Top

Published in:

01-01-2015 | 2014 SSAT Plenary Presentation

Reappraisal of Peritoneal Washing Cytology in 984 Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Margin-Negative Resection

Authors: Sohei Satoi, Yoshiaki Murakami, Fuyuhiko Motoi, Kenichiro Uemura, Manabu Kawai, Masanao Kurata, Masayuki Sho, Ippei Matsumoto, Hiroaki Yanagimoto, Tomohisa Yamamoto, Masamichi Mizuma, Michiaki Unno, Yasushi Hashimoto, Seiko Hirono, Hiroki Yamaue, Goro Honda, Minako Nagai, Yoshiyuki Nakajima, Makoto Shinzeki, Takumi Fukumoto, A-Hon Kwon

Published in: Journal of Gastrointestinal Surgery | Issue 1/2015

Abstract

Objective

The objective of the present study was to reappraise the clinical value of peritoneal washing cytology (CY) in 984 pancreatic ductal adenocarcinoma patients who underwent margin-negative resection.

Methods

In a 2001–2011 database from seven high-volume surgical institutions in Japan, 69 patients (7 %) had positive CY (CY+ group) indicative of M1 disease and 915 patients had negative CY (CY− group). Clinicopathological data and survival were compared between groups.

Results

Significant correlations between CY+ and high CA19-9 level, pancreatic body and tail cancer, lymph node metastasis, and a lower frequency of R0 resection were observed. Overall survival (OS) of CY+ patients was significantly worse than that of CY− patients (median survival time [MST], 16 vs. 25 months; 3-year OS rate, 6 vs. 37 %; p < 0.001). CY+ patients had a significantly higher rate of post-operative peritoneal carcinomatosis than CY− patients (48 vs. 21 %; p < 0.001). Administration of adjuvant chemotherapy did not provide a favorable survival outcome to CY+ patients. The current study showed that patients with M1 disease had acceptable MST after margin-negative resection and a high incidence of peritoneal carcinomatosis within 3 years after surgery, resulting in decreased long-term survival. The development of a new strategy to control peritoneal carcinomatosis when surgical resection is performed in such patients is required.

Takai S, Satoi S, Toyokawa H, et al. Clinicopathologic evaluation after resection for ductal adenocarcinoma of the pancreas: a retrospective, single-institution experience. Pancreas. 2003;26:243–9.PubMedCrossRef

Conlon KC, Klimstra DS, Brennan MF. Long term survival after curative resection for pancreatic ductal adenocarcinoma. Ann Surg. 1996;223:273–9.PubMedCentralPubMedCrossRef

Adham M, Jaeck D, Le Borgne J, et al. Long-term survival (5–20 years) after pancreatectomy for pancreatic ductal adenocarcinoma: a series of 30 patients collected from 3 institutions. Pancreas. 2008;37:352–7.PubMedCrossRef

Schnelldorfer T, Ware AL, Sarr MG, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg. 2008;247:456–62.PubMedCrossRef

Han SS, Jang JY, Kim SW, et al. Analysis of long-term survivors after surgical resection for pancreatic cancer. Pancreas. 2006;32:271–5.PubMedCrossRef

Edge SBB DR., Compton CC, Fritz AG, et al., Eds. AJCC Cancer Staging Manual (ed 7th edition). New York: Springer; 2010. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. (2010);17: 1471–4.

Ferrone CR, Haas B, Tang L et al. The influence of positive peritoneal cytology on survival in patients with pancreatic adenocarcinoma. J Gastrointest Surg. 2006;10:1347–53.PubMedCrossRef

Yoshioka R, Saiura A, Koga R et al. The implication of positive peritoneal cytology in potentially resectable pancreatic cancer. World J Surg. 2012;36:2187–91.PubMedCrossRef

Yamada S, Takeda S, Fujii T et al. Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis. Ann Surg. 2007;246:254–8.PubMedCentralPubMedCrossRef

10.

Yachida S, Fukushima N, Sakamoto M et al. Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer. Br J Surg. 2002;89:573–8.PubMedCrossRef

11.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Pancreatic Adenocarcinoma. Version 1.2014. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site [Accessed 20 January 2014].

12.

Motoi F, Rikiyama T, Katayose Y, et al. Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines. Ann Surg Oncol. 2011; 18:371–9.PubMedCrossRef

13.

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17:1471–4.PubMedCrossRef

14.

Sobin L, Gospodarowicz M, Wittekind C e. TNM Classification of Malignant Tumours, 7th ed. New York: Wiley-Liss, 2009.

15.

Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15:2403–13.PubMed

16.

Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.PubMedCrossRef

17.

Clark CJ, Traverso LW. Positive peritoneal lavage cytology is a predictor of worse survival in locally advanced pancreatic cancer. Am J Surg. 2010;199:657–62.PubMedCrossRef

18.

Yamada S, Fujii T, Kanda M, et al. Value of peritoneal cytology in potentially resectable pancreatic cancer. Brit J Surg. doi: 10.1002/bjs.9307.

19.

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.PubMedCrossRef

20.

Ueno H, Ioka T, Ikeda M, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31:1640–8.PubMedCrossRef

21.

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369:1691–703.CrossRef

22.

Shinchi H, Maemura K, Mataki Y et al. A phase II study of oral S-1 with concurrent radiotherapy followed by chemotherapy with S-1 alone for locally advanced pancreatic cancer. J Hepatobilliary Pancreat Sci. 2012; 19: 152–8.CrossRef

23.

Sudo K, Yamaguchi T, Ishihara T et al. Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer. Int J Radiat Oncol Bio Phys. 2011; 80: 119–25.CrossRef

24.

Thomassen I, Lemmens VE, Nienhuijs SW, et al. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study. Pancreas. 2013;42:72–5.PubMedCrossRef

25.

Yamamoto K, Shimada S, Hirota M, et al. EIPL (extensive intraoperative peritoneal lavage) therapy significantly reduces peritoneal recurrence after pancreatectomy in patients with pancreatic cancer. Int J Oncol. 2005;27:1321–8.PubMed

26.

Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15:2426–32.PubMedCrossRef

27.

Sugarbaker PH, Stuart OA, Bijelic L. Intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer: rationale and report of early data. Int J Surg Oncol. 2011;2011;161862. doi: 10.1155/2011/161862. Epub 2011 Dec 12.PubMedCentralPubMed

28.

Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21:67–70.PubMedCrossRef

Title: Reappraisal of Peritoneal Washing Cytology in 984 Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Margin-Negative Resection
Authors: Sohei Satoi
Yoshiaki Murakami
Fuyuhiko Motoi
Kenichiro Uemura
Manabu Kawai
Masanao Kurata
Masayuki Sho
Ippei Matsumoto
Hiroaki Yanagimoto
Tomohisa Yamamoto
Masamichi Mizuma
Michiaki Unno
Yasushi Hashimoto
Seiko Hirono
Hiroki Yamaue
Goro Honda
Minako Nagai
Yoshiyuki Nakajima
Makoto Shinzeki
Takumi Fukumoto
A-Hon Kwon
Publication date: 01-01-2015
Publisher: Springer US
Published in: Journal of Gastrointestinal Surgery / Issue 1/2015
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-014-2637-7

At a glance: The STEP trials

Springer Medicine

Reappraisal of Peritoneal Washing Cytology in 984 Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Margin-Negative Resection

Abstract

Objective

Methods

Results

At a glance: The STEP trials

Springer Medicine

Abstract

Objective

Methods

Results

Please log in to get access to this content

Other articles of this Issue 1/2015

Is Nasogastric or Nasojejunal Decompression Necessary Following Gastrectomy for Gastric Cancer? A Systematic Review and Meta-Analysis of Randomised Controlled Trials

SSAT Presidential Address 2014: Here Comes Generation Y!

Single-Stage Cholecystectomy at the Time of Pancreatic Necrosectomy Is Safe and Prevents Future Biliary Complications: a 20-Year Single Institutional Experience with 217 Consecutive Patients

Cost-Effectiveness of Total Pancreatectomy and Islet Cell Autotransplantation for the Treatment of Minimal Change Chronic Pancreatitis

Prevalence, Impact, and Risk Factors for Hospital-Acquired Conditions after Major Surgical Resection for Cancer: A NSQIP Analysis

Peroral Endoscopic Myotomy (POEM) for Esophageal Primary Motility Disorders: Analysis of 100 Consecutive Patients